Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000059286) titled 'Pharmacokinetics/pharmacodynamics/genome pharmacology study of the antibody-drug conjugate Sacituzumab Govitecan: multi-institutional prospective observational trial' on Oct. 4.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: Keio University
Condition:
Triple Negative Breast Cancer (TNBC)
Recruitment Status: Not Recruiting
Phase: Not selected
Date of First Enrollment: 2026/01/01
Target Sample Size: 100
Countries of Recruitment:
Japan
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067441
Published by HT Digital Content...